Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells. ...
May 7, 2013
0
0
An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine.
Apr 15, 2013
0
0
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people ...
Apr 9, 2013
0
0
New research from MIT may allow scientists to develop a test that can predict the severity of side effects of some common chemotherapy agents in individual patients, allowing doctors to tailor treatments to minimize the damage.
Apr 5, 2013
0
0
A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients, forcing treatment changes and delays that for some patients meant worse outcomes, more therapy-related complications ...
Mar 21, 2013
0
0
African-American women who survive breast cancer are more likely to develop heart failure than other women who have beaten the disease, according to research being presented at the American College of Cardiology's 62nd Annual ...
Mar 7, 2013
0
0
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Dec 24, 2012
0
0
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ...
Dec 11, 2012
0
0
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012
0
0
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...
Dec 7, 2012
0
1
